Citation Impact
Citing Papers
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
2010 StandoutNobel
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
2009 Standout
Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma
2007
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
Routine Bone Marrow Biopsy Has Little or No Therapeutic Consequence for Positron Emission Tomography/Computed Tomography–Staged Treatment-Naive Patients With Hodgkin Lymphoma
2012
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
2016 Standout
Sulfur [ 18 F]Fluoride Exchange Click Chemistry Enabled Ultrafast Late-Stage Radiosynthesis
2021 StandoutNobel
The prognostic impact of variant histology in nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG)
2013
Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group
2014
Homocysteine and vascular disease
1999 Standout
Molecular imaging in drug development
2008 Standout
Myeloid-derived suppressor cells coming of age
2018 Standout
Psoriasis
2009 Standout
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 Standout
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2015
Pathogenesis and clinical features of psoriasis
2007 Standout
Nodular Lymphocyte-Predominant Hodgkin Lymphoma
2007
Plasma Homocysteine as a Risk Factor for Dementia and Alzheimer's Disease
2002 Standout
Imaging in the era of molecular oncology
2008 StandoutNature
The Risk of Lymphoma in Patients with Psoriasis
2006
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis
2007
Vitamin D Deficiency
2007 Standout
Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes
2006 Standout
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
3D Slicer as an image computing platform for the Quantitative Imaging Network
2012 Standout
Assessing responses to cancer therapy using molecular imaging
2006
Non-Hodgkin's lymphomas in Alexandria, Egypt; incidence rates and trend study (1995–2004)
2007
Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG–PET data for clinical trials in lymphoma
2010
Global cancer statistics
2011 Standout
International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers
2013
Psoriasis
2015 Standout
Fluorescent and colorimetric probes for detection of thiols
2010 Standout
Interim [18F]fluorodeoxyglucose positron emission tomography imaging in stage I–II non-bulky Hodgkin lymphoma: would using combined positron emission tomography and computed tomography criteria better predict response than each test alone?
2012
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Immunity, Inflammation, and Cancer
2010 Standout
The usefulness of 18F‐fluorodeoxyglucose positron emission tomography (18F‐FDG‐PET) and a comparison of 18F‐FDG‐pet with 67gallium scintigraphy in the evaluation of lymphoma
2007
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2012
18F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging
2010
Family History of Hematopoietic Malignancy and Risk of Lymphoma
2005
The Emerging Hallmarks of Cancer Metabolism
2016 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
Infectious agents and lymphoma development: molecular and clinical aspects
2009
The Vitamin D and Cancer Conundrum: Aiming at a Moving Target
2010
Microenvironmental regulation of metastasis
2008 Standout
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
18F-FDG PET After 2 Cycles of ABVD Predicts Event-Free Survival in Early and Advanced Hodgkin Lymphoma
2010
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
2009 Standout
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
2014 Standout
Overview of early response assessment in lymphoma with FDG-PET
2007
Early post-transplantation positron emission tomography in patients with Hodgkin lymphoma is an independent prognostic factor with an impact on overall survival
2011
The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know
2010 Standout
Lyme borreliosis
2011 Standout
Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation
2006
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
2015 Standout
FDG PET and risk-adapted therapy in Hodgkin's and non-Hodgkin's lymphoma
2008
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
2018 Standout
Vitamin D deficiency: a worldwide problem with health consequences
2008 Standout
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Enzyme conversion immunoassay for determining total homocysteine in plasma or serum
1998
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
2015 Standout
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
2011
Role of Functional Imaging in the Management of Lymphoma
2011
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
Cost Effectiveness of Positron Emission Tomography in Patients With Hodgkin's Lymphoma in Unconfirmed Complete Remission or Partial Remission After First-Line Therapy
2010
Benefits and requirements of vitamin D for optimal health: a review.
2005
Assessment of Tumor Size Reduction Improves Outcome Prediction of Positron Emission Tomography/Computed Tomography After Chemotherapy in Advanced-Stage Hodgkin Lymphoma
2014
Revised Response Criteria for Malignant Lymphoma
2007 Standout
Positron Emission Tomography As an Imaging Biomarker
2006
The association of solar ultraviolet B (UVB) with reducing risk of cancer: multifactorial ecologic analysis of geographic variation in age-adjusted cancer mortality rates.
2006
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
Cobalamin and Folate Evaluation: Measurement of Methylmalonic Acid and Homocysteine vs Vitamin B12 and Folate
2000
Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
2012 Standout
Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation
1996
Treatment Selection and Survival Outcomes in Early-Stage Diffuse Large B-Cell Lymphoma: Do We Still Need Consolidative Radiotherapy?
2015
Cancer treatment and survivorship statistics, 2016
2016 Standout
Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity
2014
Cancer treatment and survivorship statistics, 2019
2019 Standout
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
2014 Standout
Impact of [18F] Fluorodeoxyglucose Positron Emission Tomography on Staging and Management of Early-Stage Follicular Non-Hodgkin Lymphoma
2008
18F-FDG PET/CT Imaging In Oncology
2011
Brentuximab vedotin
2012
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 Standout
Chemistry and Biology Of Multicomponent Reactions
2012 Standout
Role of [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in the Follow-Up of Lymphoma
2009
Circulating myeloid‐derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up‐front with a risk‐adapted strategy
2014
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
2007
Works of Mads Hansen being referenced
Early Interim 2-[ 18 F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study
2007
Borrelia infection and risk of non-Hodgkin lymphoma
2008
Clinical impact of FDG‐PET/CT in the planning of radiotherapy for early‐stage Hodgkin lymphoma
2006
How to diagnose cobalamin deficiency
1994
Ultraviolet Radiation Exposure and Risk of Malignant Lymphomas
2005
Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake
2006
Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study
2008
FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma
2005
Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma.
2006